Summary CEA was extracted by the perchloric acid method from primary adenocarcinomas of the colon and the ovary, from ascitic and pleural fluids from patients with pancreatic, lung and breast cancer, and from the cyst fluid of a benign ovarian cystadenoma. Further purification included gel filtration and affinity chromatography. Antisera against CEA from colon, breast, ovary, lung and pancreatic cancer were produced in rabbits. In double diffusion experiments, all these CEA samples showed a reaction of complete immunological identity with all the anti-CEA sera, whatever their origin. CEA from colon, breast, pancreas and ovary were labelled with 1251 and used in radioimmunological experiments. In a radioimmunological system where the tracer and the antiserum were constant, all the CEA used as standards gave parallel inhibition curves, having nearly identical slopes. This was another criterion of immunological identity. Sera of numerous cancer patients were assayed in several RIA systems, one of them being the classical system with colonic CEA as tracer and anti-colonic CEA as antiserum, the others being "organ specific" systems. The values obtained in these assays were found to be highly correlated: the rank coefficient of correlation between colonic and breast cancer RIA systems was rs=0.96, that between colonic and ovarian RIA systems, 0.92, that between colonic and pancreatic RIA systems, 0.97 and that between colonic and lung RIA systems 0.96. It is thus concluded that by use of different organ-derived CEA preparations and their corresponding polyclonal antisera, no significative differences in serum CEA levels may be expected. No evidence of organ specificity of serum CEA was found.
The carcinoembryonic antigen of the digestive system (CEA) was first described by Gold & Freedman (1965) as a tumour-and organ-specific antigen, as it was found only in the digestive adenocarcinomas. Later studies modified these conclusions, since CEA was found in the extracts of various non-digestive carcinomas (breast, lung, ovary, etc.) and of non-cancerous tissues (Pusztaszeri & Mach, 1973) , especially of normal colonic mucosa. As for the latter, it was shown to be identical, biochemically and immunochemically, to the CEA extracted from colonic tumours (Fritsche & Mach, 1977; Egan et al., 1977) . A similar comparison between CEA extracted from non-digestive tumours and that of the colon would be very useful; better results might be expected when assaying CEA in sera of patients with nondigestive cancers by using CEA obtained from nondigestive organs and antisera prepared against these CEA. Such studies have not been conducted before, except by Santen et al. (1980) November 1982 , accepted 22 March 1983 colon, followed by antisera against each of them. With these reagents, the problem of CEA organ specificity was investigated.
Materials and methods
Tumours/CEA source Surgical tumour specimens of primary colon cancer (n =110) and primary ovarian cancer (n =10) -both of the adenocarcinoma type -as well as ascitic and pleural fluids from patients with breast cancer (n = 3), lung cancer (n = 1), pancreatic cancer (n = 1), and a cyst fluid of a patient with benign ovarian cystadenoma were used for CEA extraction. CEA-radioimmunoassay CEA preparations used as tracer were labelled by the Chloramine T method (Hunter & Greenwood, 1962) . Briefly, 5-15,pg of CEA were labelled with 300 uCi Na125I (Hoechst AG) for 30-45 min at room temperature. The tracer was separated from free iodine on Sephadex G50 fine (1 x 15 cm column) and further purified on Sephadex G200 (1.5 x 35 cm column). After establishing the relationship between immunoreactive antigen and antibody in dilution curves, the tracer was diluted to a working dilution and stored frozen in 10 ml portions until use.
The RIA was developed as double antibody test: the first antibody was anti-CEA IgG from the rabbit and the second an anti-rabbit-IgG-antiserum from a goat. For direct serum determinations, aliquots of CEA-free serum were added to standard dilutions (2.5-160 ng ml-).
Statistical analysis Statistical comparison of the regression coefficients of the different standard inhibition curves and the Spearman's rank coefficient of correlation of serum CEA determinations by different CEA radioimmunoassay systems were computed by conventional methods (Sachs, 1972) .
Results
CEA preparations and antisera CEA preparations and antisera are summarised in Table I . As shown in Figure 1 , the different CEA (Lamerz & Ruider, 1976 Antibody dilution curves All the anti-CEA sera were used to bind labelled CEAs of different origins. The binding capacity and the slope of the dilution curves were nearly the same when a given tracer was studied with different antisera: this is shown in Figure 2 where the binding of CEA-PA by antisera against CEA-CO, CEA-OV, CEA-MT and CEA-PA in comparison to an anti-NCA-serum is depicted. Similar results were obtained with other tracers. The antibody titre varied from one antiserum to another (50% end point of antibody dilution between 1/120,000 for A-CEA-CO, 1/15,000 for A-CEA-PA, A-CEA-MT, A-CEA-BC and 1/7,000 for A-CEA-OV).
Standard inhibition curves
The results of many experiments can be summarized as follows:
(1) Within one RIA system where the tracer and the first antibody were the same, different inhibitors, i.e. CEA identical 'to the tracer or originating from other organs, gave parallel inhibition curves: the slopes of these curves were the same. Figures 3 and 4 show some of the inhibition curves obtained when 2 standards (CEA from pancreas and colon) were compared in one RIA system. Other experiments gave similar results. (2) When the same tracer was tested with 2 different antisera, one of them specific for the CEA originating from the same organ as the tracer, and the other prepared with a CEA of different origin, inhibition curves were obtained in each case with the 2 CEA standards corresponding to the antisera. The slopes of these curves, i.e. the B values of the logit-log regression lines reported in Table II as tracer (Table II, All these data lead to the conclusion that the CEAs of different origins have the same inhibiting capacity, i.e. are antigenically identical. However, the labelling procedure might alter their reactivity in a manner which differs from one sanmple to another. It does not appear that the organ origin of CEA samples makes them more or less sensitive to this alteration, as colonic CEA itself gave variable results following iodination. Hence heterogeneity of the tracers plays a major role in the difference *between inhibition curves. Finally, there is certainly some heterogeneity among the antisera which could also influence the variations between curves. E Serum CEA determinations Sera of patients with gastrointestinal, breast, pancreas, ovary and lung cancer, or cancer of unknown primary origin were assayed for CEA content in different RIA systems: they were used to inhibit the binding of radiolabelled CEAs (of various origins) to their respective antisera. Figures  5 and 6 show that whatever the antiserum and the tracer, the CEA values were highly correlated. The rank coefficients of correlation were rs = 0.992 (P< 10-3; n=91) when the ovarian and colonic RIA systems were compared, and rs = 0.979 (P < 10-3; n= 126) when the pancreatic and the colonic RIA systems were studied in parallel. The rs values were 0.978 (P < 10-3; n = 117) for the comparison between breast and colonic RIA systems, and 0.969 (P<10-3; n=119) for the comparison between the lung and colonic RIA systems (Figures 5 and 6 CEA CEA-BC It is thus clear that when the serum of a nondigestive cancer (breast, lung, ovary) was assayed in (i) the conventional RIA, performed with colonic CEA as tracer and standard and anti-colonic CEA serum and (ii) "organ specific RIA", made with the CEA extracted from the same organ as that afflicted by the patient's cancer and the corresponding antiserum the CEA values thus obtained were the same or nearly identical in almost all cases.
Discussion
It is clear that our results do not support the hypothesis of an organ specificity of CEA. All the CEA samples gave reactions of identity in Ouchterlony plates when reacted in criss-cross experiments with antisera against these CEA samples. Furthermore, the inhibition curves given by these CEAs were parallel: this is strong evidence CEA obunc ngw -1 Figure 6 Serum CEA levels of patients with various malignancies. Correlation between CEA values determined by a reference colonic cancer CEA RIA system and a breast cancer CEA RIA system (above) and a lung cancer CEA RIA system (below).
